Your Muscles Hurt Constantly, Yet Nothing Seems to Help. Here's Why.

COMT (catechol-O-methyltransferase) is an enzyme that breaks down catecholamines: dopamine, norepinephrine, and epinephrine. These molecules are central to how your brain gates pain signals and produces endogenous analgesia (natural pain relief). When COMT is working optimally, pain signals get modulated appropriately; when it’s sluggish, pain amplification persists.

The Val158Met variant, carried by roughly 25% of people with European ancestry in homozygous slow form, creates a COMT enzyme that works at a fraction of normal speed. This slow clearance of dopamine and norepinephrine means your brain stays in a pain-amplified state longer after any tissue stress. Even mild muscle fatigue gets interpreted as severe pain because the neurochemicals that normally suppress pain signaling linger inefficiently.

You feel it as chronic soreness that seems disproportionate to your actual activity level. A light workout leaves you sore for days. Sitting in one position becomes uncomfortable. Your nervous system is essentially stuck in a pain-amplification loop because it can’t clear the neurotransmitters that enable pain-gating.

OPRM1 encodes the mu-opioid receptor, the brain’s primary target for endogenous opioids (your body’s natural morphine-like molecules). Your brain produces these constantly as part of normal pain management. The more responsive your OPRM1 receptors are, the more effective this natural pain relief becomes.

The A118G variant (G allele), present in roughly 10-15% of people with European ancestry, creates receptors that are less sensitive to endogenous opioids. This means your brain’s built-in pain-relief system is muted at the receptor level; you produce the molecules but they don’t activate pain-gating as effectively. The result is a lower natural pain threshold and reduced recovery from tissue stress.

You experience it as a persistent ache that doesn’t respond to your body’s own pain-management attempts. Rest, relaxation, and even vigorous exercise (which should trigger endogenous opioid release) don’t provide the relief they should. Your muscles never fully “recover” because the neurochemical signal for pain relief isn’t getting through.

MTHFR (methylenetetrahydrofolate reductase) converts dietary folate into its active form, methylfolate, which your cells use for methylation reactions. One of those critical reactions is the synthesis of nitric oxide (NO), a molecule that regulates blood flow to muscles and modulates pain signaling in the nervous system.

The C677T variant, carried by roughly 40% of people with European ancestry, reduces MTHFR enzyme efficiency by 40-70%. This impairs nitric oxide production, which means blood flow to recovering muscles decreases and pain-signaling neurons stay overexcited. You can eat a diet rich in folate and still be functionally depleted at the cellular level.

You feel it as muscles that stay tight and sore despite adequate stretching and massage, combined with a sensation that your muscles aren’t getting “fed” properly after exertion. Recovery is slow, cramping is common, and vasodilation (the sensation of a “pump” or warm blood flow) during or after exercise feels muted. Tissue repair is sluggish because the vascular support for recovery isn’t there.

BDNF (brain-derived neurotrophic factor) is a growth factor that shapes how your nervous system responds to repeated stimuli. In the context of pain, BDNF drives central sensitization: the process where your brain’s pain-processing circuits become increasingly sensitive to pain signals over time. This is useful in small amounts (helps you avoid repeated injury), but when dysregulated, it locks your nervous system into chronic pain mode.

The Val66Met variant, carried by roughly 30% of people, alters BDNF activity and trafficking. People carrying the Met allele have altered pain sensitization dynamics; their nervous systems “learn” pain more readily and are slower to unlearn it. What starts as acute muscle soreness becomes encoded in your central nervous system as a chronic pain state.

You experience it as pain that persists long after the original tissue injury should have healed, combined with a phenomenon called allodynia (pain from stimuli that normally aren’t painful). Gentle touch, temperature changes, or light pressure become uncomfortable. Your nervous system has essentially memorized the pain state and is reinforcing it with each repeated signal.

GCH1 (GTP cyclohydrolase 1) is an enzyme that catalyzes the first step of tetrahydrobiopterin (BH4) synthesis. BH4 is a critical cofactor for multiple neurotransmitter-synthesizing enzymes, including those that produce serotonin, dopamine, and nitric oxide. All of these are central to pain modulation. People with higher GCH1 activity produce more BH4 and tolerate pain better.

Certain GCH1 variants reduce enzyme activity, lowering BH4 availability in pain-processing neurons. This depletes the cofactor needed for pain-modulating neurotransmitter synthesis, leaving your nervous system more vulnerable to pain amplification. Roughly 15-20% of the population carries variants that reduce GCH1 activity.

You feel it as a generalized lowering of your pain threshold. Activities that others find mildly uncomfortable feel acutely painful to you. Muscle soreness after exercise feels sharper and lasts longer. Minor tissue stress (a minor strain, overuse, poor sleeping posture) triggers disproportionate pain because your nervous system lacks the BH4-dependent buffering systems that normally suppress pain signals.

FAAH (fatty acid amide hydrolase) is an enzyme that breaks down anandamide, a neurotransmitter in your endocannabinoid system. Anandamide activates the same receptors (CB1 and CB2) as cannabis, but it’s produced by your own body and plays a crucial role in pain modulation, stress buffering, and mood regulation. The slower FAAH clears anandamide, the more available it is for pain relief.

The C385A variant (A allele), present in roughly 20-30% of the population, reduces FAAH enzyme activity. This means anandamide lingers longer in your synapses, providing prolonged endocannabinoid-mediated pain suppression and stress buffering. People carrying the A allele are genetically predisposed to lower pain sensitivity and better natural pain management.

If you carry the common CC variant (faster FAAH), you experience the opposite: anandamide clears rapidly, leaving you without adequate endocannabinoid-mediated pain relief. This means your nervous system lacks one of its primary pain-suppression tools. You feel it as chronic muscle aches that don’t respond well to standard analgesics, combined with difficulty recovering emotionally from physical exertion (because anandamide also regulates mood and stress resilience).